Studies were undertaken in anesthetized dogs on the acute effect of 100 mg of gemfibrozil i.v. on arterial plasma free fatty acid (FFA) and glycerol concentrations. On a structural basis it was thought conceivable that the drug might cause (transient) elevation in plasma FFA concentrations, a contraindication for administration of the drug to patients with ischmmic heart disease, since they are at risk from further ischaemia.
Blood samples were taken 10 min and immediately preceding the injection of gemfibrozil and at 5, 10, 15 and 30 min thereafter. During basal lipolysis, gemfibrozil did not alter plasma FFA ( A, attenuationfactor were made based on plasma gemfibrozil concentrations determined by a gas chromatographic procedure using 2, 2-dimethyl-5-(xylyloxy) hexanoic acid (Fig 3) . This internal standard has the advantage over the butyric analogue of gemfibrozil as an internal standard that it allows qualitative and quantitative estimation of plasma FFA as well as the determination of drug levels.
